Table 1.

The clinical characteristic and ASNS level in non-small cell lung-cancer patients (N = 92).

Characteristic			COX regression model
			P*	HR(95%CI)
Age	(30–84 years)		0.781	1.079 (0.63,1.85)
	30–50(9,10%)
	50–70(61,66%)
	70–84(23,24%)
Sex	male(49,53%)		0.524	1.202 (0.682,2.117)
	female(43,47%)
Pathological degree	I–III		0.527	0.840 (0.491,1.44)
	I(3,3%); II(61,66%);III(28,31%)
Tumor size	(1.5–14 cm)		0.416	1.183 (0.788,1.776)
	1.5–3.0(18,20%)
	3.0–4.5(45,49%)
	≥4.5(29,31%)
lymph invasion	positive(58,63%)		0.806	0.897 (0.375,2.145)
	negative(34,37%)
Clinical stages	I–IV		0.001	2.081 (1.343,3.224)
	I(28,30%); II(17,18%);III(47,52,%)
ASNS expression**	cancer tissue (IHC score)
	in nuclues	83%low(117 ± 57); 17%high(330 ± 77)	0.014	3.837 (1.313,11.214)
	in cytoplasm	68%low(131 ± 33); 32%high(297 ± 60)	0.065	2.114 (0.954,4.683)
	para-cancer tissue (IHC score)
	in nuclues	65%low(92 ± 23); 35%high(180 ± 42)	0.686	1.262 (0.41,3.885)
	in cytoplasm	60%low(77 ± 13); 40%high(124 ± 26)	0.237	0.473 (0.137,1.635)

^*P-value was calculated by COX regression model;

^**ASNS expression were detected by immunohistochemistry.